{"id":"https://openalex.org/W2604523879","doi":"https://doi.org/10.1097/ftd.0000000000000400","title":"Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Spondyloarthritis","display_name":"Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Spondyloarthritis","publication_year":2017,"publication_date":"2017-04-05","ids":{"openalex":"https://openalex.org/W2604523879","doi":"https://doi.org/10.1097/ftd.0000000000000400","mag":"2604523879","pmid":"https://pubmed.ncbi.nlm.nih.gov/28379895"},"language":"en","primary_location":{"id":"doi:10.1097/ftd.0000000000000400","doi":"https://doi.org/10.1097/ftd.0000000000000400","is_oa":false,"landing_page_url":"https://doi.org/10.1097/ftd.0000000000000400","pdf_url":null,"source":{"id":"https://openalex.org/S179268941","display_name":"Therapeutic Drug Monitoring","issn_l":"0163-4356","issn":["0163-4356","1536-3694"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Therapeutic Drug Monitoring","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5053266441","display_name":"Fr\u00e9d\u00e9ric Medina","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I110017253","display_name":"Universit\u00e9 de Tours","ror":"https://ror.org/02wwzvj46","country_code":"FR","type":"education","lineage":["https://openalex.org/I110017253"]},{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]}],"countries":["FR"],"is_corresponding":true,"raw_author_name":"Fr\u00e9d\u00e9ric Medina","raw_affiliation_strings":["Rheumatology Department and Pharmacology-Toxicology Laboratory, Universit\u00e9 Fran\u00e7ois-Rabelais de Tours, CNRS, UMR 7292, Tours, France; and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rheumatology Department and Pharmacology-Toxicology Laboratory, Universit\u00e9 Fran\u00e7ois-Rabelais de Tours, CNRS, UMR 7292, Tours, France; and","institution_ids":["https://openalex.org/I110017253","https://openalex.org/I1294671590"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113858719","display_name":"Chamaida Plasencia","orcid":"https://orcid.org/0000-0003-3503-9047","observed_orcids":["https://orcid.org/0000-0003-3503-9047"]},"institutions":[{"id":"https://openalex.org/I2800562746","display_name":"Hospital Universitario La Paz","ror":"https://ror.org/01s1q0w69","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I2800562746"]},{"id":"https://openalex.org/I4210103477","display_name":"Hospital La Paz Institute for Health Research","ror":"https://ror.org/017bynh47","country_code":"ES","type":"facility","lineage":["https://openalex.org/I4210103477"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Chamaida Plasencia","raw_affiliation_strings":["Rheumatology Department and Health Research Institute (Idipaz), Hospital Universitario de La Paz, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rheumatology Department and Health Research Institute (Idipaz), Hospital Universitario de La Paz, Madrid, Spain","institution_ids":["https://openalex.org/I2800562746","https://openalex.org/I4210103477"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031211618","display_name":"Philippe Goupille","orcid":"https://orcid.org/0000-0002-8605-1567","observed_orcids":["https://orcid.org/0000-0002-8605-1567"]},"institutions":[{"id":"https://openalex.org/I110017253","display_name":"Universit\u00e9 de Tours","ror":"https://ror.org/02wwzvj46","country_code":"FR","type":"education","lineage":["https://openalex.org/I110017253"]},{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]}],"countries":["FR"],"is_corresponding":true,"raw_author_name":"Philippe Goupille","raw_affiliation_strings":["Rheumatology Department and Pharmacology-Toxicology Laboratory, Universit\u00e9 Fran\u00e7ois-Rabelais de Tours, CNRS, UMR 7292, Tours, France; and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rheumatology Department and Pharmacology-Toxicology Laboratory, Universit\u00e9 Fran\u00e7ois-Rabelais de Tours, CNRS, UMR 7292, Tours, France; and","institution_ids":["https://openalex.org/I110017253","https://openalex.org/I1294671590"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039278929","display_name":"Gilles Paintaud","orcid":"https://orcid.org/0000-0003-0158-1356","observed_orcids":["https://orcid.org/0000-0003-0158-1356"]},"institutions":[{"id":"https://openalex.org/I110017253","display_name":"Universit\u00e9 de Tours","ror":"https://ror.org/02wwzvj46","country_code":"FR","type":"education","lineage":["https://openalex.org/I110017253"]},{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]}],"countries":["FR"],"is_corresponding":true,"raw_author_name":"Gilles Paintaud","raw_affiliation_strings":["Rheumatology Department and Pharmacology-Toxicology Laboratory, Universit\u00e9 Fran\u00e7ois-Rabelais de Tours, CNRS, UMR 7292, Tours, France; and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rheumatology Department and Pharmacology-Toxicology Laboratory, Universit\u00e9 Fran\u00e7ois-Rabelais de Tours, CNRS, UMR 7292, Tours, France; and","institution_ids":["https://openalex.org/I110017253","https://openalex.org/I1294671590"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054608926","display_name":"Alejandro Balsa","orcid":"https://orcid.org/0000-0001-8070-7062","observed_orcids":["https://orcid.org/0000-0001-8070-7062"]},"institutions":[{"id":"https://openalex.org/I2800562746","display_name":"Hospital Universitario La Paz","ror":"https://ror.org/01s1q0w69","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I2800562746"]},{"id":"https://openalex.org/I4210103477","display_name":"Hospital La Paz Institute for Health Research","ror":"https://ror.org/017bynh47","country_code":"ES","type":"facility","lineage":["https://openalex.org/I4210103477"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Alejandro Balsa","raw_affiliation_strings":["Rheumatology Department and Health Research Institute (Idipaz), Hospital Universitario de La Paz, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rheumatology Department and Health Research Institute (Idipaz), Hospital Universitario de La Paz, Madrid, Spain","institution_ids":["https://openalex.org/I2800562746","https://openalex.org/I4210103477"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5018062347","display_name":"Denis Mulleman","orcid":"https://orcid.org/0000-0003-4089-7513","observed_orcids":["https://orcid.org/0000-0003-4089-7513"]},"institutions":[{"id":"https://openalex.org/I110017253","display_name":"Universit\u00e9 de Tours","ror":"https://ror.org/02wwzvj46","country_code":"FR","type":"education","lineage":["https://openalex.org/I110017253"]},{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]}],"countries":["FR"],"is_corresponding":true,"raw_author_name":"Denis Mulleman","raw_affiliation_strings":["Rheumatology Department and Pharmacology-Toxicology Laboratory, Universit\u00e9 Fran\u00e7ois-Rabelais de Tours, CNRS, UMR 7292, Tours, France; and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rheumatology Department and Pharmacology-Toxicology Laboratory, Universit\u00e9 Fran\u00e7ois-Rabelais de Tours, CNRS, UMR 7292, Tours, France; and","institution_ids":["https://openalex.org/I110017253","https://openalex.org/I1294671590"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5018062347","https://openalex.org/A5031211618","https://openalex.org/A5039278929","https://openalex.org/A5053266441"],"corresponding_institution_ids":["https://openalex.org/I110017253","https://openalex.org/I1294671590"],"apc_list":null,"apc_paid":null,"fwci":0.2884,"has_fulltext":false,"cited_by_count":10,"citation_normalized_percentile":{"value":0.2267148,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":98},"biblio":{"volume":"39","issue":"4","first_page":"360","last_page":"363"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11092","display_name":"Spondyloarthritis Studies and Treatments","score":0.7681000232696533,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11092","display_name":"Spondyloarthritis Studies and Treatments","score":0.7681000232696533,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.2168000042438507,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10134","display_name":"Inflammatory Bowel Disease","score":0.002400000113993883,"subfield":{"id":"https://openalex.org/subfields/2715","display_name":"Gastroenterology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/spondyloarthritis","display_name":"spondyloarthritis","score":0.9340000152587891},{"id":"https://openalex.org/keywords/biopharmaceuticals","display_name":"biopharmaceuticals","score":0.9710000157356262},{"id":"https://openalex.org/keywords/tumor-necrosis-factor-inhibitors","display_name":"tumor necrosis factor inhibitors","score":0.9950000047683716},{"id":"https://openalex.org/keywords/antidrug-antibodies","display_name":"antidrug antibodies","score":0.9660000205039978},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7639999985694885},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9070000052452087},{"id":"https://openalex.org/keywords/concentration-response-relationship","display_name":"concentration-dependent effects","score":0.7860000133514404},{"id":"https://openalex.org/keywords/immunogenicity","display_name":"immunogenicity","score":0.8930000066757202},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.7720000147819519},{"id":"https://openalex.org/keywords/dose-adjustment","display_name":"dose adjustment","score":0.7770000100135803}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7602615356445312},{"id":"https://openalex.org/C2781047461","wikidata":"https://www.wikidata.org/wiki/Q679692","display_name":"Biopharmaceutical","level":2,"score":0.7547607421875},{"id":"https://openalex.org/C2780272996","wikidata":"https://www.wikidata.org/wiki/Q1261151","display_name":"Therapeutic drug monitoring","level":3,"score":0.7429494857788086},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6995910406112671},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.6731497049331665},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.6303427219390869},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.54522305727005},{"id":"https://openalex.org/C2780868878","wikidata":"https://www.wikidata.org/wiki/Q1660197","display_name":"Immunogenicity","level":3,"score":0.5033864378929138},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.46676915884017944},{"id":"https://openalex.org/C59491497","wikidata":"https://www.wikidata.org/wiki/Q864715","display_name":"Biosimilar","level":2,"score":0.4370361566543579},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.1805466115474701},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.14765477180480957},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.14721360802650452},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.056643158197402954},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.05394631624221802}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001688","descriptor_name":"Biological Products","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D001688","descriptor_name":"Biological Products","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001702","descriptor_name":"Biopharmaceutics","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D001702","descriptor_name":"Biopharmaceutics","qualifier_ui":"Q000639","qualifier_name":"trends","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013167","descriptor_name":"Spondylitis, Ankylosing","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D013167","descriptor_name":"Spondylitis, Ankylosing","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D016903","descriptor_name":"Drug Monitoring","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D016903","descriptor_name":"Drug Monitoring","qualifier_ui":"Q000639","qualifier_name":"trends","is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1097/ftd.0000000000000400","doi":"https://doi.org/10.1097/ftd.0000000000000400","is_oa":false,"landing_page_url":"https://doi.org/10.1097/ftd.0000000000000400","pdf_url":null,"source":{"id":"https://openalex.org/S179268941","display_name":"Therapeutic Drug Monitoring","issn_l":"0163-4356","issn":["0163-4356","1536-3694"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Therapeutic Drug Monitoring","raw_type":"journal-article"},{"id":"pmid:28379895","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28379895","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Therapeutic drug monitoring","raw_type":"Journal Article"},{"id":"pmh:oai:HAL:hal-01980745v1","doi":null,"is_oa":false,"landing_page_url":"https://univ-tours.hal.science/hal-01980745","pdf_url":null,"source":{"id":"https://openalex.org/S4306402512","display_name":"HAL","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4405252976","host_organization_name":"Centre pour la Communication Scientifique Directe","host_organization_lineage":["https://openalex.org/I4405252976"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Therapeutic Drug Monitoring, 2017, 39 (4), pp.360-363. ⟨10.1097/FTD.0000000000000400⟩","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":36,"referenced_works":["https://openalex.org/W1849982557","https://openalex.org/W1982017993","https://openalex.org/W2008114701","https://openalex.org/W2046414057","https://openalex.org/W2078886781","https://openalex.org/W2092460713","https://openalex.org/W2096200590","https://openalex.org/W2101141197","https://openalex.org/W2104131294","https://openalex.org/W2106691018","https://openalex.org/W2110732019","https://openalex.org/W2113771841","https://openalex.org/W2120557677","https://openalex.org/W2122042072","https://openalex.org/W2122404129","https://openalex.org/W2125389744","https://openalex.org/W2125412490","https://openalex.org/W2129301243","https://openalex.org/W2130303906","https://openalex.org/W2133606090","https://openalex.org/W2133745994","https://openalex.org/W2133832905","https://openalex.org/W2137101132","https://openalex.org/W2151701758","https://openalex.org/W2169911848","https://openalex.org/W2177257388","https://openalex.org/W2230111957","https://openalex.org/W2260435046","https://openalex.org/W2278932593","https://openalex.org/W2305878652","https://openalex.org/W2317900027","https://openalex.org/W2557319878","https://openalex.org/W2591114082","https://openalex.org/W2598577802","https://openalex.org/W2610764164","https://openalex.org/W2610804525"],"related_works":["https://openalex.org/W2734864562","https://openalex.org/W2761161155","https://openalex.org/W3197194315","https://openalex.org/W3087471093","https://openalex.org/W2933737230","https://openalex.org/W7100871582","https://openalex.org/W2958302608","https://openalex.org/W2328992665","https://openalex.org/W2137992121","https://openalex.org/W4399974146"],"abstract_inverted_index":{"Treatment":[0],"of":[1,32,72,78,83,122,149,157,166],"spondyloarthritis":[2],"(SpA)":[3],"has":[4],"greatly":[5],"improved":[6],"in":[7,109,133],"the":[8,30,44,48,52,70,76,96,102,158,161],"biopharmaceutical":[9],"era.":[10],"These":[11],"compounds,":[12],"primarily":[13],"tumor":[14],"necrosis":[15],"factor":[16],"inhibitors,":[17],"are":[18],"effective,":[19],"but":[20],"some":[21,37,137],"patients":[22],"may":[23,40],"show":[24],"poor":[25],"response,":[26],"sometimes":[27],"due":[28],"to":[29,68],"presence":[31],"antidrug":[33],"antibodies":[34],"(ADAs).":[35],"In":[36,90],"instances,":[38],"clinicians":[39],"increase":[41],"or":[42,119],"taper":[43],"dose,":[45],"depending":[46],"on":[47,60],"clinical":[49,54,131],"response.":[50],"Besides":[51],"current":[53],"practice,":[55],"a":[56,66,154],"tailored":[57],"strategy":[58],"based":[59],"drug":[61,81,128,147],"monitoring":[62,82,148],"is":[63,87,135],"emerging":[64],"as":[65],"way":[67],"improve":[69],"use":[71],"these":[73,167],"drugs.":[74,168],"However,":[75],"relevance":[77],"this":[79,91],"therapeutic":[80,146],"biopharmaceuticals":[84,150],"for":[85,151],"SpA":[86,110,134,152],"still":[88],"unknown.":[89],"literature":[92],"review,":[93],"we":[94],"examined":[95],"most":[97],"relevant":[98],"articles":[99],"dealing":[100],"with":[101,112,117],"concentration-response":[103],"relation,":[104],"ADA":[105],"detection,":[106],"and":[107,130,142,164],"pharmacokinetics":[108],"treated":[111],"biopharmaceuticals.":[113],"ADAs":[114],"were":[115],"associated":[116],"low":[118],"undetectable":[120],"concentration":[121,129],"monoclonal":[123],"antibodies.":[124],"The":[125],"relation":[126],"between":[127],"response":[132],"debated,":[136],"studies":[138],"showing":[139],"an":[140],"association":[141,159],"others":[143],"not.":[144],"Therefore,":[145],"requires":[153],"better":[155],"understanding":[156],"among":[160],"pharmacokinetics,":[162],"pharmacodynamics,":[163],"immunogenicity":[165]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":5}],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2017-04-14T00:00:00"}